Daisy Robinton, Oviva Therapeutics co-founder and CEO

A new spin­out wades in­to ovar­i­an ag­ing, armed with a seed round and ex­per­i­men­tal drugs from Mass Gen­er­al

There aren’t many biotechs em­pha­siz­ing women’s health, but a new spin­out is try­ing to change that.

Ovi­va Ther­a­peu­tics, a pipeline com­pa­ny of New York-based Cam­bri­an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.